Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Santé Canada Auteur : Hanan Abramovici Ph.D. Co-auteurs : Sophie-Anne Lamour, Ph.D. et George Mammen, Ph.D. Nous republions cet excellent document de Santé Canada, et surtout, le résumé des indications reconnues, et envisagées, du cannabis thérapeutique. Aperçu des énoncés récapitulatifs Les énoncés récapitulatifs suivants visent à résumer le contenu des sections 4.0 (Usages thérapeutiques possibles) et 7.0 (Effets indésirables) et leurs sous-sections respectives. Les énoncés récapitulatifs peuvent être également trouvés dans leurs sections et sous-sections respectives dans le corps même du document. Remarque: la plupart des études [...]
Lire la suiteThe Past and Future of Psychedelic Science : An Introduction to This Issue Richard E. Doblin, Merete Christiansen, Lisa Jerome, Brad Burge JOURNAL OF PSYCHOACTIVE DRUGS, 2019, VOL. 51, NO. 2, 93–97 https://doi.org/10.1080/02791072.2019.1606472 ABSTRACT Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of scientific and cultural exploration in the1950s and ‘60s, psychedelic research was [...]
Lire la suiteFrom local to global—Fifty years of research on Salvia divinorum Ivan Casselman, Catherine J. Nock, Hans Wohlmuth, Robert P. Weatherby, Michael Heinrich Journal of Ethnopharmacology, 2014, 151, 768–783 http://dx.doi.org/10.1016/j.jep.2013.11.032 a b s t r a c t Ethnopharmacological relevance : In 1962 ethnopharmacologists, Hofmann and Wasson, undertook an expedition to Oaxaca,Mexico. These two researchers were the first scientists to collecta flowering specimen of Salvia divinorum allowing theidentification ofthisspecies.Whilet he species'traditional use is confined to a very small region of Mexico, since Hofmann and Wasson's expedition 50 years ago, Salvia divinorum has become globally recognized for its main active constituent, the diterpene salvinorin A, which has [...]
Lire la suiteThe association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study Nadav Shalita, Jürgen Rehmb, Shaul Lev-Ran Psychiatry Research, 2019, 278, 70–77 https://doi.org/10.1016/j.psychres.2019.05.041 A B S T R A C T Both personality disorders (PD) and cannabis use are highly comorbid with various psychiatric disorders. While previous research indicates specific interactions between cannabis use and schizotypal PD associated with schizophrenia, research into cannabis use among individuals with other PDs and the development of several additional psychiatric disorders is scarce. We explored the prevalence and incidence of psychiatric disorders among individuals with PDs who use cannabis, and whether individuals [...]
Lire la suiteA Psychotherapeutic View on the Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Addiction Anja LOIZAGA-VELDER MAPS Bulletin Special Edition, Spring 2013, 36-40. Ayahuasca is a traditional plant preparation of the Amazon basin with psychoactive properties. In recent decades ayahuasca has gained the attention of researchers in multiple disciplines worldwide due to its acclaimed therapeutic and spiritual qualities. It is an admixture of two plants : the harmaline containing vine Banisteriopsis caapi, and the DMT-containing leafs from the Psychotria viridis bush. It is typically administered by a trained expert in a ritual context. The use of ayahuasca has spread beyond the Amazon [...]
Lire la suiteLifetime marijuana use in relation to insulin resistance in lean, overweight, and obese US adults Gerard Ngueta, Ruth Ndjaboue Journal of Diabetes, 2019 https://doi.org/10.1111/1753-0407.12958 Abstract Background Obese individuals are more likely to show insulin resistance (IR). However, limited population studies on marijuana use with markers of IR have yielded mixed results. The aim of this study was to examine the association of marijuana use with IR in US adults with different body mass index (BMI) status. Methods Data from the 2009 to 2016 National Health and Nutrition Examination Survey (NHANES) were abstracted. Minimal lifetime marijuana use was estimated using the duration of regular exposure and frequency of use. [...]
Lire la suiteFlavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer Michele Moreau, Udoka Ibeh, Kaylie Decosmo Noella Bih, Sayeda Yasmin-Karim, Ngeh Toyang, Henry Lowe5 and Wilfred Ngwa Frontiers in Oncology, July 2019, Vol. 9, article 660. doi: 10.3389/fonc.2019.00660 Abstract Pancreatic cancer is particularly refractory to modern therapies, with a 5-year survival rate for patients at a dismal 8%. One of the significant barriers to effective treatment is the immunosuppressive pancreatic tumor microenvironment and development of resistance to treatment. New treatment options to increase both the survival and quality of life of patients are urgently needed. This study reports on a new [...]
Lire la suiteNabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial Jose M. Trigo, Alexandra Soliman, Lena C. Quilty, Benedikt Fischer, JuÈrgen Rehm, Peter Selby, Allan J. Barnes11¤a, Marilyn A. Huestis, Tony P. George, David L. Streiner, Gregory Staios, Bernard Le Foll PLoS ONE, 2018, 13, (1), e0190768. https://doi.org/10.1371/journal.pone.0190768 Abstract Background The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex®) can decrease cannabis withdrawal symptoms. Here, we assessed in a pilot study the [...]
Lire la suiteIntegrating Psychedelic Medicines and Psychiatry : Theory and Methods of a Model Clinic Jordan Sloshower Chapter 7, In : Labate B., Cavnar C. (eds) : Plant Medicines, Healing and Psychedelic Science, 2018 © Springer International Publishing AG 2018 DOI: 10.1007/978-3-319-76720-8_7 Abstract The past two decades has seen a significant increase in both popular and scientific interest in psychedelic substances and plants as therapeutics for mental illness, addictions, and psychospiritual suffering. Current psychiatric practice privileges a biological paradigm in which the brain is considered the locus of mental illness and symptom-focused treatments are delivered to patients as passive recipients. In contrast, a psychedelic healing paradigm, constructed through [...]
Lire la suitePsychedelic drug use in healthy individuals : a review of benefits, costs, and implications for drug policy James W.B. Elsey Drug Science, Policy and Law, 2017, Vol 3, 1-11 DOI: 10.1177/2050324517723232 Abstract The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so. This review considers contemporary research into the use of psychedelic drugs in healthy individuals, including neurobiological and subjective effects. In line with findings [...]
Lire la suite